The long and short of long-acting antiretroviral therapy for HIV

The first of many new and emerging long-acting antiretroviral therapy (LA ART) regimens recently received FDA approval for the treatment and prevention of HIV infection. The panel discusses LA ART and its impact on clinical practice. 

The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.